Search Results - "Hann, Christine"

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 by Ready, Neal, Farago, Anna F, de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D, Schneider, Jeffrey G, Spigel, David R, Moreno, Victor, Chau, Ian, Hann, Christine L, Eder, Joseph Paul, Steele, Nicola L, Pieters, Anne, Fairchild, Justin, Antonia, Scott J

“…For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2,…”
Get more information

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study by Morgensztern, Daniel, Besse, Benjamin, Greillier, Laurent, Santana-Davila, Rafael, Ready, Neal, Hann, Christine L, Glisson, Bonnie S, Farago, Anna F, Dowlati, Afshin, Rudin, Charles M, Le Moulec, Sylvestre, Lally, Satwant, Yalamanchili, Sreeni, Wolf, Jürgen, Govindan, Ramaswamy, Carbone, David P

“…Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short…”
Get full text

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline by Rudin, Charles M, Ismaila, Nofisat, Hann, Christine L, Malhotra, Narinder, Movsas, Benjamin, Norris, Kim, Pietanza, M Catherine, Ramalingam, Suresh S, Turrisi, 3rd, Andrew T, Giaccone, Giuseppe

“…The American College of Chest Physicians (ACCP) produced an evidence-based guideline on treatment of patients with small-cell lung cancer (SCLC). Because of…”
Get full text

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort by Ready, Neal E, Ott, Patrick A, Hellmann, Matthew D, Zugazagoitia, Jon, Hann, Christine L, de Braud, Filippo, Antonia, Scott J, Ascierto, Paolo A, Moreno, Victor, Atmaca, Akin, Salvagni, Stefania, Taylor, Matthew, Amin, Asim, Camidge, D Ross, Horn, Leora, Calvo, Emiliano, Li, Ang, Lin, Wen Hong, Callahan, Margaret K, Spigel, David R

“…Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and…”
Get more information

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC by Mohammad, Helai P., Smitheman, Kimberly N., Kamat, Chandrashekhar D., Soong, David, Federowicz, Kelly E., Van Aller, Glenn S., Schneck, Jess L., Carson, Jeffrey D., Liu, Yan, Butticello, Michael, Bonnette, William G., Gorman, Shelby A., Degenhardt, Yan, Bai, Yuchen, McCabe, Michael T., Pappalardi, Melissa B., Kasparec, Jiri, Tian, Xinrong, McNulty, Kenneth C., Rouse, Meagan, McDevitt, Patrick, Ho, Thau, Crouthamel, Michelle, Hart, Timothy K., Concha, Nestor O., McHugh, Charles F., Miller, William H., Dhanak, Dashyant, Tummino, Peter J., Carpenter, Christopher L., Johnson, Neil W., Hann, Christine L., Kruger, Ryan G.

“…Epigenetic dysregulation has emerged as an important mechanism in cancer. Alterations in epigenetic machinery have become a major focus for targeted therapies…”
Get full text

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer by Rudin, Charles M, Reck, Martin, Johnson, Melissa L, Blackhall, Fiona, Hann, Christine L, Yang, James Chih-Hsin, Bailis, Julie M, Bebb, Gwyn, Goldrick, Amanda, Umejiego, John, Paz-Ares, Luis

“…Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis. Initial responses to standard-of-care chemo-immunotherapy are,…”
Get full text

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer by Pietanza, M Catherine, Waqar, Saiama N, Krug, Lee M, Dowlati, Afshin, Hann, Christine L, Chiappori, Alberto, Owonikoko, Taofeek K, Woo, Kaitlin M, Cardnell, Robert J, Fujimoto, Junya, Long, Lihong, Diao, Lixia, Wang, Jing, Bensman, Yevgeniva, Hurtado, Brenda, de Groot, Patricia, Sulman, Erik P, Wistuba, Ignacio I, Chen, Alice, Fleisher, Martin, Heymach, John V, Kris, Mark G, Rudin, Charles M, Byers, Lauren Averett

“…Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized,…”
Get full text

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer by Shankar, Bairavi, Zhang, Jiajia, Naqash, Abdul Rafeh, Forde, Patrick M, Feliciano, Josephine L, Marrone, Kristen A, Ettinger, David S, Hann, Christine L, Brahmer, Julie R, Ricciuti, Biagio, Owen, Dwight, Toi, Yukihiro, Walker, Paul, Otterson, Gregory A, Patel, Sandip H, Sugawara, Shunichi, Naidoo, Jarushka

“…The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune…”
Get more information

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy by Suresh, Karthik, Psoter, Kevin J, Voong, Khinh Ranh, Shankar, Bairavi, Forde, Patrick M, Ettinger, David S, Marrone, Kristen A, Kelly, Ronan J, Hann, Christine L, Levy, Benjamin, Feliciano, Josephine L, Brahmer, Julie R, Feller-Kopman, David, Lerner, Andrew D, Lee, Hans, Yarmus, Lonny, Hales, Russell K, D'Alessio, Franco, Danoff, Sonye K, Naidoo, Jarushka

“…With increasing use of immune checkpoint inhibitors (ICIs) for advanced NSCLC, there is increasing recognition of immune-related adverse events associated with…”
Get more information

Persistent mutation burden drives sustained anti-tumor immune responses by Niknafs, Noushin, Balan, Archana, Cherry, Christopher, Hummelink, Karlijn, Monkhorst, Kim, Shao, Xiaoshan M., Belcaid, Zineb, Marrone, Kristen A., Murray, Joseph, Smith, Kellie N., Levy, Benjamin, Feliciano, Josephine, Hann, Christine L., Lam, Vincent, Pardoll, Drew M., Karchin, Rachel, Seiwert, Tanguy Y., Brahmer, Julie R., Forde, Patrick M., Velculescu, Victor E., Anagnostou, Valsamo

“…Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed to consistently demonstrate clinical utility in predicting responses…”
Get full text

DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms by Yao, James, Bergsland, Emily, Aggarwal, Rahul, Aparicio, Ana, Beltran, Himisha, Crabtree, Judy S, Hann, Christine L, Ibrahim, Toni, Byers, Lauren A, Sasano, Hironobu, Umejiego, John, Pavel, Marianne

“…Neuroendocrine neoplasms (NEN) are heterogeneous malignancies that can arise at almost any anatomical site and are classified as biologically distinct…”
Get full text

Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model by MacDiarmid, Jennifer A, Langova, Veronika, Bailey, Dale, Pattison, Scott T, Pattison, Stacey L, Christensen, Neil, Armstrong, Luke R, Brahmbhatt, Vatsala N, Smolarczyk, Katarzyna, Harrison, Matthew T, Costa, Marylia, Mugridge, Nancy B, Sedliarou, Ilya, Grimes, Nicholas A, Kiss, Debra L, Stillman, Bruce, Hann, Christine L, Gallia, Gary L, Graham, Robert M, Brahmbhatt, Himanshu

“…Cytotoxic chemotherapy can be very effective for the treatment of cancer but toxicity on normal tissues often limits patient tolerance and often causes…”
Get full text

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors by GANDHI, Leena, CAMIDGE, D. Ross, DIVE, Caroline, ENSCHEDE, Sari H, NOLAN, Cathy, CHIU, Yi-Lin, BUSMAN, Todd, HAO XIONG, KRIVOSHIK, Andrew P, HUMERICKHOUSE, Rod, SHAPIRO, Geoffrey I, RUDIN, Charles M, DE OLIVEIRA, Moacyr Ribeiro, BONOMI, Philip, GANDARA, David, KHAIRA, Divis, HANN, Christine L, MCKEEGAN, Evelyn M, LITVINOVICH, Elizabeth, HEMKEN, Philip M

“…Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and…”
Get full text

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis by Suresh, Karthik, Naidoo, Jarushka, Zhong, Qiong, Xiong, Ye, Mammen, Jennifer, de Flores, Marcia Villegas, Cappelli, Laura, Balaji, Aanika, Palmer, Tsvi, Forde, Patrick M, Anagnostou, Valsamo, Ettinger, David S, Marrone, Kristen A, Kelly, Ronan J, Hann, Christine L, Levy, Benjamin, Feliciano, Josephine L, Lin, Cheng-Ting, Feller-Kopman, David, Lerner, Andrew D, Lee, Hans, Shafiq, Majid, Yarmus, Lonny, Lipson, Evan J, Soloski, Mark, Brahmer, Julie R, Danoff, Sonye K, D'Alessio, Franco

“…Checkpoint inhibitor pneumonitis (CIP) is a highly morbid complication of immune checkpoint immunotherapy (ICI), one which precludes the continuation of ICI…”
Get full text

Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer by POIRIER, J. T, DOBROMILSKAYA, Irina, MORIARTY, Whei F, PEACOCK, Craig D, HANN, Christine L, RUDIN, Charles M

“…We assessed the efficacy of Seneca Valley virus (SVV-001), a neuroendocrine cancer-selective oncolytic picornavirus, in primary heterotransplant mouse models…”
Get full text

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors by LORUSSO, Patricia M, RUDIN, Charles M, GRAHAM, Richard A, ZERIVITZ, Kenn L, LOW, Jennifer A, VON HOFF, Daniel D, REDDY, Josina C, TIBES, Raoul, WEISS, Glen J, BORAD, Mitesh J, HANN, Christine L, BRAHMER, Julie R, CHANG, Ilsung, DARBONNE, Walter C

“…The hedgehog (Hh) signaling pathway, a key regulator of cell growth and differentiation during development is implicated in pathogenesis of certain cancers…”
Get full text

Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer by Sivapalan, Lavanya, Iams, Wade T, Belcaid, Zineb, Scott, Susan C, Niknafs, Noushin, Balan, Archana, White, James R, Kopparapu, Prasad, Cann, Christopher, Landon, Blair V, Pereira, Gavin, Velculescu, Victor E, Hann, Christine L, Lovly, Christine M, Anagnostou, Valsamo

“…Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis, calling for improved real-time noninvasive biomarkers of therapeutic…”
Get full text

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449 by Rudin, Charles M, Hann, Christine L, Laterra, John, Yauch, Robert L, Callahan, Christopher A, Fu, Ling, Holcomb, Thomas, Stinson, Jeremy, Gould, Stephen E, Coleman, Barbara, LoRusso, Patricia M, Von Hoff, Daniel D, de Sauvage, Frederic J, Low, Jennifer A

“…The hedgehog pathway is essential for certain aspects of embryonic differentiation. Abnormalities of this pathway have been found in some cases of…”
Get full text

Report of the First International Symposium on NUT Carcinoma by French, Christopher A, Cheng, Michael L, Hanna, Glenn J, DuBois, Steven G, Chau, Nicole G, Hann, Christine L, Storck, Simone, Salgia, Ravi, Trucco, Matteo, Tseng, Jennifer, Stathis, Anastasios, Piekarz, Richard, Lauer, Ulrich M, Massard, Christophe, Bennett, Kelly, Coker, Shodeinde, Tontsch-Grunt, Ulrike, Sos, Martin L, Liao, Sida, Wu, Catherine J, Polyak, Kornelia, Piha-Paul, Sarina A, Shapiro, Geoffrey I

“…NUT carcinoma is a rare, aggressive cancer defined by rearrangements of the NUTM1 gene. No routinely effective treatments of NUT carcinoma exist, despite…”
Get full text

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer by Marrone, Kristen A., Zhou, Xian, Forde, Patrick M., Purtell, Michael, Brahmer, Julie R., Hann, Christine L., Kelly, Ronan J., Coleman, Barbara, Gabrielson, Edward, Rosner, Gary L., Ettinger, David S.

“…Background In the absence of a targeted oncogenic driver mutation or high programmed death‐ligand 1 expression, systemic therapy with platinum‐based doublet…”
Get full text